MPM BioImpact’s Aktis Oncology AKTS Stock Holding History

MPM BioImpact’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$156M	Hold	4,835,872	–	–	9.5%	2
2026 Q1	$86.5M	Buy	+4,835,872	New	+$93.9M	6.68%	3

Other funds holding AKTS

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

MPM BioImpact's AKTS Position: Q2 2026 in Review

MPM BioImpact held its Aktis Oncology (AKTS) position steady in Q2 2026 at 4,835,872 shares worth $156M. The position accounts for 9.5% of the portfolio, ranked #2.

MPM BioImpact first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

MPM BioImpact held 4,835,872 shares of Aktis Oncology worth $156M as of Q2 2026.
MPM BioImpact left its Aktis Oncology share count unchanged in Q2 2026.
Aktis Oncology made up 9.5% of MPM BioImpact's portfolio in Q2 2026, its #2 holding.
MPM BioImpact first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.